COMPANY

Advenchen Laboratories

Advenchen Laboratories's website says: “Advenchen Laboratories is a small pharmaceutical company focusing on pharmaceutical research and development involving small molecule cancer drug discovery programs.” From company website Source · Oct 12, 2026

Keywords: small molecule Leiomyosarcoma Synovial Sarcoma Soft-Tissue Sarcoma Non-small Cell Lung Cancer Endometrial Carcinoma Ovarian Carcinoma Fallopian Tube Carcinoma Primary Peritoneal Carcinoma Cervical Carcinoma Sarcoma,Soft Tissue Gynecologic Cancer Endometrial Cancer Ovarian Cancer Cervical Cancer AL3818 AL8326

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

May 19, 2022 Trial start Phase 1: A Study of AL8326 in Non-Small Cell Lung Cancer source ↗
Oct 26, 2021 Trial start I: A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. source ↗
Aug 15, 2017 Trial start III: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) source ↗
2015-12 Trial start 1: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma ( source ↗
2015-11 Trial start 1: Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) source ↗

Upcoming milestones

2027-12 (ESTIMATED) · III · Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) · NCT03016819
2027-12 (ESTIMATED) · Phase 1 · A Study of AL8326 in Non-Small Cell Lung Cancer · NCT06794957
Nov 7, 2029 (ESTIMATED) · I · A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. · NCT07392736

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT03016819	Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)	III	Recruiting	Aug 15, 2017	2027-12 (estimated)
NCT07392736	A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.	I	Recruiting	Oct 26, 2021	Nov 7, 2029 (estimated)
NCT06794957	A Study of AL8326 in Non-Small Cell Lung Cancer	Phase 1	Active, not recruiting	May 19, 2022	2027-12 (estimated)
NCT02584478	Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	1	Unknown status (ClinicalTrials.gov)	2015-12	2024-10 (estimated)
NCT05612191	Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)	Not listed	Available	Not listed	Not listed
NCT02558348	Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	1	Terminated	2015-11	Feb 14, 2017 (actual)